NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia (slow heart rate) due to sick sinus syndrome and/or atrioventricular block
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults
Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..
Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin
Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip
Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion
Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma
Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy
NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C
Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism
Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of
NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures
NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks
Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...
NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...